Felix Gonzalez
Scientific Director Bristol Myers Squibb
Seminars
Wednesday 27th January 2027
Target protein degradation: Harnessing CRBN to discover potential breakthrough therapeutics
4:30 pm
- Elucidating thalidomide’s MoA led to realizing the promise of harnessing CRBN for targeted protein degradation
- Structural insight into cereblon ternary complexes is guiding the optimization of targeted protein degraders
- This platform is enabling the selective degradation of pathways implicated in multiple diseases
